Canadian Real-World Evidence: Observational 24-Week Outcomes for Health Care Practitioner Authorized Cannabis
Real-world evidence offers valuable insight into how medical cannabis performs outside randomized controlled trials, capturing outcomes across diverse patient populations and product types to help inform real-world clinical decision making.
Driving Biopharmaceutical Advancement
of Evidence-Based, Cannabinoid Products
Who We Are
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products. with a focus on the medical and pharmaceutical market segments at an international level, Avicanna has established an industry leading scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.
•AN IMPORTANT STATEMENT FROM AVICANNA •
MEDICAL CANNABIS
IN VETERAN'S CARE:
PROPOSED REIMBURSEMENT CHANGES
Integrated Cannabinoid-Based Biopharmaceutical Platform
Commercial & Medical Platform
4 integrated commercial-stage business units
50+ proprietary commercialized cannabinoid products
Commercial presence across 20+ international markets
$25.5M revenue, near EBITDA breakeven during 2025
Scientific & Clinical Platform
Proprietary intellectual property and formulation technologies
Clinical and real-world evidence programs
Partnerships with leading academic and clinical institutions
Indication-specific pharmaceutical pipeline
Core Business Units
Medical Cannabis Products (RHO Phyto™)
Medical Cannabis Care Platform (MyMedi.ca)
Pharmaceutical Pipeline
Active pharmaceutical ingredients (Aureus Santa Marta™)
Four Commercial Stage Business Pillars
Avicanna’s Scientific Platform Has Resulted In 50+ Proprietary Formulations and Commercial Products
A vertically integrated platform spanning API, R&D, clinical development, and patient care.
Medical Cannabis Products
Industry Leading Scientific Platform
Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products
Scientific Platform
R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products
50+ Proprietary
Commercial Products
10+ Scientists
Pipeline
IP Portfolio including
USPTO granted patents
11 Canadian Government Research
Grants Awarded Since 2020
All IP and Trade Secrets
Academic and Clinical Collaborations Since 2017
World-Class Institutional Collaborations
Clinical Development
Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products
08.08.2021
Products & Pipeline
Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products
